Veltassa (patiromer) / CSL Behring - LARVOL DELTA

Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy. (PubMed, Pharmacoecon Open) - "Applying DIAMOND data, patiromer is deemed to be cost-effective at a willingness-to pay threshold of €40,000 per QALY gained in Italy."

HEOR • Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

scCompass: An Integrated Multi-Species scRNA-seq Database for AI-Ready. (PubMed, Adv Sci (Weinh)) - "By applying standardized data pre-processing, scCompass integrates and curates transcriptomic data from nearly 105 million single cells across 13 species...Different scalable datasets are provided that can be easily adapted for AI model training and the pretrained checkpoints with state-of-the-art single-cell foundation models. In summary, scCompass is highly efficient and scalable database for AI-ready, which combined with user-friendly data sharing, visualization, and online analysis, greatly simplifies data access and exploitation for researchers in single-cell biology (http://www.bdbe.cn/kun)."

Journal

Practice Patterns of Potassium-binding Agent Use for Severe Acute Hyperkalemia in Intensive Care Units (ATS 2025) - " Using PINC AI Healthcase Database, we identified adults (age ≥18) with severe hyperkalemia (serum potassium ≥6.0 mmol/L) admitted to ICUs May 2018 - September 2022 and received any of three potassium-binding agents: Sodium polystyrene sulfate (SPS; Kayexalate®), sodium zirconium cyclosilicate (SZC; Lokelma®), or patiromer. Few ICU patients with severe acute hyperkalemia received a potassium-binding agent on presentation, but if used, there was significant variation between hospitals in the choice of agent. We theorize this may be partly explained by the high cost of new potassium-binding agents relative to SPS. Notably, the use of new potassium-binding agents increased although no comparative effectiveness clinical trials have been completed to date."

Cardiovascular • Critical care • Nephrology • Renal Disease

PAT-CHINA-303: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (clinicaltrials.gov) - P3 | N=290 | Recruiting | Sponsor: Vifor Fresenius Medical Care Renal Pharma | N=200 ➔ 290

Enrollment change • Chronic Kidney Disease • Nephrology • Renal Disease

Real-World Effectiveness of Patiromer Among Hemodialysis (HD) Patients Prescribed Various Treatment Schedules Over a One-Year Follow-Up (ERA 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence

Updates in chronic kidney disease management: A systematic review. (PubMed, Pharmacotherapy) - "Currently, SGLT2i have demonstrated consistent benefits with large effect sizes in preventing the progression of CKD, solidifying this class as a first-line treatment along with RASi. Subsequent consideration for GLP-1RA, finerenone, and sacubitril/valsartan should be dependent on patient-specific comorbidities, while potassium binders may allow for longer use of RASi."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

PRINCE: Patiromer and Diet/hrQoL in Chronic Dialysis (clinicaltrials.gov) - P3 | N=40 | Not yet recruiting | Sponsor: Mario Negri Institute for Pharmacological Research

HEOR • New P3 trial • Chronic Kidney Disease • Nephrology • Renal Disease

PAT-CHINA-303: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Vifor Fresenius Medical Care Renal Pharma | Trial completion date: Mar 2026 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease

Comparison Among Potassium Binders on the Management of Hyperkalemia on Chronic Dialysis Patients: A Protocol for Systematic Review. (PubMed, G Ital Nefrol) - "The main aim is to evaluate the difference in serum potassium concentration after treatment with sodium zirconium cyclosilicate or patiromer compared to placebo/sodium polystyrene sulfonate/calcium polystyrene sulfonate. Conclusions. The present protocol for a systematic review will consider all existing evidence from published RCTs about the efficacy of HIF-PHIs on hemodialysis patients."

Journal • Renal Disease

Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study. (PubMed, Clin Exp Nephrol) - "Patiromer can improve hyperkalemia by lowering sK-level and can suppress the recurrence of hyperkalemia with continued administration, and is safe and easy-to-use for a wide range of patients."

Journal • P3 data

EMERALD 2: Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Vifor Pharma, Inc. | Trial completion date: Aug 2028 ➔ Dec 2030 | Trial primary completion date: Aug 2027 ➔ Dec 2029

Trial completion date • Trial primary completion date

Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial. (PubMed, Heart Fail Rev) - "Patiromer and sodium zirconium cyclosilicate (SZC), two novel potassium binders, have emerged as highly effective and safe tools for managing hyperkalemia and enabling the optimization of MRA therapy. This mini-review critically examines the findings of the recently published REALIZE-K (Randomized Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone) trial, placing it within the broader context of current evidence on potassium binders and their potential role in mitigating hyperkalemia to optimize MRA treatment. Moreover, it explores other significant barriers to MRA optimization, including clinician concerns over the risk of hyperkalemia, a consistent and pervasive issue that often leads to treatment inertia. By addressing both physiological and psychological barriers, this review aims to provide a comprehensive understanding of..."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

The role of cation-exchange resins in hyperkalemia management. (PubMed, Med J Armed Forces India) - "The management of hyperkalemia has evolved, incorporating calcium polystyrene sulfonate (CPS) and newer agents such as sodium zirconium cyclosilicate (SZC) and patiromer alongside traditional treatments. The findings suggest a shift toward newer potassium-binding agents in clinical practice, underscored by the need for individualized treatment approaches based on patient-specific factors. This article aims to guide clinicians in optimizing hyperkalemia management, ensuring effective, safe, and patient-centered care."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

COMPARATIVE EFFECTIVENESS OF THREE POTASSIUM EXCHANGERS IN THE ACUTE MANAGEMENT OF HYPERKALEMIA: SODIUM ZIRCONIUM CYCLOSILICATE, SODIUM POLYSTYRENE SULFONATE, AND PATIROMER. (WRMC 2025) - "Conclusions More patients who received SPS achieved a post-intervention potassium level ≤ 5.5 mmol/L, but this finding was not statistically significant likely due to our small sample size. Authors plan to finalize data collection and analysis in the coming months."

HEOR • Cardiovascular • Diabetes

EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. (PubMed, Cardiorenal Med) - "We convened a consensus panel to describe the optimal management across multiple clinical settings when caring for patients with hyperkalemia. This consensus emphasizes a multidisciplinary approach to managing hyperkalemia, particularly in patients with cardiovascular kidney metabolic (CKM) syndrome, to avoid fragmentation of care and ensure comprehensive treatment strategies. The primary goal of this manuscript is to describe strategies to maintain cardiovascular benefits of essential medications while effectively managing potassium levels."

Journal • Review • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

The Association of Heart Failure and Edema Events between Patients Initiating SZC or Patiromer (CVCT USA 2024) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department. (PubMed, Open Access Emerg Med) - "In this study of patients with acute hyperkalemia in the ED setting, concurrent administration of patiromer did not result in more sustained potassium reduction compared to insulin alone in the overall cohort. The trend in favor of adjunct patiromer in the subgroup with adequate renal function warrants further investigation."

Journal • Retrospective data • Renal Disease

Evaluation of Current Utilization and Dosing Strategies of Patiromer in Pediatric Patients (ASHP 2024) - No abstract available

Clinical • Pediatrics

Prevalence, knowledge, and awareness of needle stick injuries among nursing students in Palestine and associated factors. (PubMed, Infect Dis Health) - "Training programs are necessary to reduce the risk of blood-borne disease transmission and improve workplace safety for nursing students. Clinical nursing administrators should create practical plans to lower the incidence of NSIs."

Journal • Infectious Disease

Mineralocorticoid Receptor Antagonist (MRA) Use Patterns following Potassium Binder Initiation: Insights from the DEMONSTRATE Database (KIDNEY WEEK 2024) - "This study aims to investigate the treatment pattern of MRA following initiation of treatment with potassium binders. From the DEMONSTRATE database (six regions in mid-Sweden) patients with at least one pharmacy dispensation of first (sodium polystyrene sulfonate, SPS) or second-generation (patiromer or sodium zirconium cyclosilicate, SZC) potassium binders between 2005 and 2022 were selected, prescriptions were estimated and treatment episodes were established. 2,146 and 280 patients were treated with MRA and initiated first and second-generation K+ binders.The second-generation users tended to have a higher comorbidity profile. MRA-treated patients had a high comorbidity profile and compared to the first-generation potassium binders, patients initiating second generation potassium binders had more comorbidities and longer K+ binder treatment duration. Overall, potassium binder users still dose reduced MRA to a large degree. Whether second generation binders lead to..."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Nephrology

Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders. (PubMed, Heart Fail Rev) - "In recent years, the development of new potassium binders, specifically patiromer and sodium zirconium cyclosilicate (SZC), has revolutionized the management of hyperkalemia. The introduction of patiromer and SZC offers significant advantages over traditional therapies, providing effective and better-tolerated options for patients. The review highlights the role of these novel agents in contemporary hyperkalemia management and calls for ongoing research to further refine treatment protocols and improve patient outcomes."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Gastrointestinal Disorder • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists. (PubMed, Adv Kidney Dis Health) - "Two potassium (K+) binders-patiromer sorbitex calcium and sodium zirconium cyclosilicate-are recommended by international guidelines for the management of hyperkalemia. Consensus was reached on the following topics: (1) identifying risk factors for hyperkalemia; (2) serum K+ monitoring before and during K+ binder use; (3) utilizing K+ binders in patients receiving renin-angiotensin-aldosterone system inhibitors and dialysis; and (4) when to initiate K+ binders and their duration of use. These consensus statements for the use of K+ binders may assist the nephrology community in optimizing management of hyperkalemia in patients across the spectrum of CKD."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

PAT-CHINA-303: Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Vifor Fresenius Medical Care Renal Pharma | Trial completion date: Dec 2026 ➔ Mar 2026 | Trial primary completion date: Dec 2026 ➔ Dec 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease